Antiarrhythmic Effect of Artemisinin in an Ex-vivo Model of Brugada Syndrome Induced by NS5806
Sign Up to like & getrecommendations! Published in 2023 at "Korean Circulation Journal"
DOI: 10.4070/kcj.2022.0312
Abstract: Author's summary According to current guidelines, an implantable cardioverter-defibrillator (ICD) is the first-line therapy for Brugada syndrome. But, fundamentally, ICD is not a therapeutic modality. We have quinidine. However, it has several adverse effects. The… read more here.
Keywords: vivo model; antiarrhythmic effect; artemisinin vivo; effect artemisinin ... See more keywords